Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
Topics
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
Netherlands Moves to Cut Mental Health Wait Times for 2026
The Dutch Healthcare Institute prioritizes group therapy and preventive mental health care to reduce long wait times under its 2026–2028 appropriate care agenda.
BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts
CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.
ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
CMS Reopens National TAVR Coverage Review at Edwards’ Request
CMS has accepted Edwards Lifesciences’ request to reopen the national coverage determination for TAVR, launching a review that could expand access to asymptomatic patients and ease procedural barriers by late 2026.
ICER Backs Wegovy, Zepbound Value in Obesity but Flags Access Crunch
The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more